Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer

January 28, 2016

Jamal-Hanjani et al. 2016 Ann Oncol.

Annals of Oncology

Jamal-Hanjani M, Wilson GA, Horswell S, Mitter R, Sakarya O, Constantin T, Salari R, Kirkizlar E, Sigurjonsson S, Pelham R, Kareht S, Zimmermann B, Swanton C. Ann Oncol. 2016 May;27(5):862-7.

Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer

Elevations of dd-cfDNA before bpAR ProActive Study Publication with Supplement April 2024

Personalized tumor-informed circulating tumor DNA assay for detecting minimal residual disease in non-small cell lung cancer patients rece

US physician perspective on the use of biomarker and ctDNA testing in patients with melanoma

Detection of circulating tumor DNA with ultradeep sequencing of plasma cell‐free DNA for monitoring minimal residual disease and early detec

Early real-world experience monitoring circulating tumor DNA in resected early-stage non–small cell lung cancer

Distinct Molecular Processes Mediate Donor-derived Cell-free DNA Release From Kidney Transplants in Different Disease States

Impact of high‐risk prenatal screening results for 22q11.2 deletion syndrome on obstetric and neonatal management: Secondary analysis from t

Validation of an Enhanced Version of a Single- Nucleotide Polymorphism-Based Noninvasive Prenatal Test for Detection of Fetal Aneuploidies

Informatics-based, highly accurate, noninvasive prenatal paternity testing

Letter to the Editor by Megan Hall in response to Munne S.

Detection of triploid, molar, and vanishing twin pregnancies by a single-nucleotide polymorphismebased noninvasive prenatal test

Validation of a Single-Nucleotide Polymorphism-Based Non-Invasive Prenatal Test in Twin Gestations: Determination of Zygosity, Individual Fe

De novo HRAS gene mutation associated with Costello syndrome identified by non-invasive cell-free fetal DNA screening

Re: Clinical experience across the fetal-fraction spectrum of a non-invasive prenatal screening approach with low test-failure rate

Estimating the relative frequency of leukodystrophies and recommendations for carrier screening in the era of next-generation sequencing

Primary cell-free DNA screening or contingent screening for the common trisomies: a response

Performance of noninvasive prenatal screening for 22q11.2 deletion syndrome in the SMART study

Why Cell‐Free DNA Can Be a “Game Changer” for Lung Allograft Monitoring for Rejection and Infection

Letter to the Editors: Performance of Donor-derived Cell-free DNA Assays in Kidney Transplant Patients

Using both the Fraction and Quantity of Donor-Derived Cell-Free DNA to Detect Kidney Allograft Rejection